Related Experiment Videos
Autologous formalin-fixed tumor vaccine
1Tsukuba Laboratory, Cell-Medicine, Inc., Koyadai 2-1, Tsukuba Science City, Ibaraki 305-0074, Japan. tad-ohno@cell-medicine.com
Current Pharmaceutical Design
|April 28, 2005
Summary
A novel tumor vaccine shows promise in preventing hepatocellular carcinoma recurrence. Clinical trials indicate significantly longer time before recurrence and improved survival rates with minimal adverse effects.
Area of Science:
- Oncology
- Immunotherapy
- Vaccine Development
Background:
- Hepatocellular carcinoma (HCC) resection can lead to tumor recurrence.
- Adjuvant therapies are crucial for improving post-surgical outcomes in cancer patients.
- Novel vaccine strategies are being explored to enhance anti-tumor immunity.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel autologous tumor vaccine in patients with resected HCC.
- To assess the vaccine's impact on recurrence rates and survival.
- To determine the potential of this vaccine in preventing cancer recurrence after surgery.
Main Methods:
- Development of a novel tumor vaccine combining autologous formalin-fixed tumor fragments, cytokine-encapsulated microparticles, and an adjuvant.
- Phase I/IIa clinical trial in post-resection HCC patients.
- Phase IIb randomized clinical trial to assess recurrence-free survival (RFS) and overall survival (OS).
Main Results:
- Phase I/IIa trial showed a significantly longer time to first recurrence compared to historical controls, with no significant adverse effects.
- Phase IIb trial demonstrated significant improvements in RFS and OS rates.
- Median follow-up in the Phase IIb trial was 15 months.
Conclusions:
- The novel autologous tumor vaccine is safe and effective in reducing HCC recurrence post-resection.
- The vaccine significantly improves patient survival outcomes.
- This therapeutic approach holds promise for preventing recurrence in various human cancers after surgical resection.